BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events

ME Staff 8-k
-
0

BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01 Other Events

On July5, 2017, BeiGene,Ltd. (the “Company”) issued a press release announcing the dosing of the first patient in a pivotal clinical trial of BGB-A317, an investigational humanized monoclonal antibody, in China designed to investigate the efficacy and safety of BGB-A317 in patients with previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer. The full text of the Company’s press release is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release issued on July5, 2017

***


BeiGene, Ltd. Exhibit
EX-99.1 2 a17-16066_1ex99d1.htm EX-99.1 Exhibit 99.1   BeiGene,…
To view the full exhibit click here

About BEIGENE,LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

BEIGENE,LTD. (NASDAQ:BGNE) Recent Trading Information

BEIGENE,LTD. (NASDAQ:BGNE) closed its last trading session up +9.36 at 54.36 with 211,606 shares trading hands.